Security National Financial Corporation Announces Q3 Earnings Call - Security National Finl (NASDAQ:SNFCA)

Kelun-Biotech's Phase III trial showed sac-TMT reduced death risk by 31% vs. chemo in EGFR-mutant NSCLC. No new safety concerns emerged. The data supports prior PFS results and China approval, with global regulatory wins and NRDL expansions as potential catalysts for wider adoption.

Genmab (NASDAQ:GMAB) reported Phase 2 trial data for petosemtamab in metastatic colorectal cancer, showing 75% and 67% response rates in first- and second-line patients, respectively. The trial involved 79 patients and was presented at the European Society for Medical Oncology Congress 2026. Genmab is conducting four Phase 3 trials and will host an investor update.

Agenus Inc. reported Phase 2 NEOASIS study results, showing 83% MPR and 72% pCR in 18 dMMR colon cancer patients treated with botensilimab plus balstilimab. The company aims to expand use across tumors, pending further studies and regulatory discussions.

NovaBridge Biosciences (NBP) selected an 8 mg/kg dose for givastomig in Phase 3 trials, aligning with the FDA on a global study protocol for treating metastatic gastroesophageal adenocarcinoma. The company reported mature Phase 1b data, moving the drug into a registrational program.

Agenus' botensilimab and balstilimab combination therapy showed 83% of patients with locally advanced dMMR colon cancer had little or no cancer remaining at surgery. The NEOASIS study met its primary endpoint, with mild side effects reported. Agenus is exploring organ preservation in rectal cancer and advancing the approach in MSS colon cancer. The company aims to reduce treatment duration and chemotherapy use.

NovaBridge (Nasdaq: NBP) presented updated Phase 1b data for givastomig, showing 79% response rate in metastatic gastroesophageal adenocarcinoma. The 8 mg/kg dose was selected for registrational development. FDA engagement and designations support its path. A webcast is scheduled for November 2, 2026.